| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Menbutone does not have a well-defined molecular target. Its primary action is as a choleretic, promoting the flow of bile and aiding in the digestion of fats. Its mechanism of action involves stimulation of bile secretion, which may be mediated through effects on the liver and biliary system. It also acts as trypsinogen and pepsinogen, potentially affecting digestive processes.
|
|---|---|
| ln Vitro |
In vitro, menbutone is characterized as a choleretic agent. Its activity is typically assessed by its ability to stimulate bile secretion in isolated liver perfusion models. Its effects as trypsinogen and pepsinogen may be evaluated in enzymatic assays.
|
| ln Vivo |
In vivo, menbutone acts as a choleretic, stimulating bile secretion. It has a rapid onset of action, reaching its maximum plasma level within 1 hour and lasting for roughly 10 hours. It is used to promote the flow of bile and aid in fat digestion. Its potential therapeutic applications have been studied in hepatic and gastrointestinal disorders.
|
| Enzyme Assay |
In vitro enzyme/receptor binding studies are not applicable to menbutone, as its mechanism is not based on enzyme or receptor binding. Its choleretic activity is evaluated using functional assays measuring bile flow in isolated liver preparations. Its effects on trypsinogen and pepsinogen may be assessed using standard enzymatic activity assays.
|
| Cell Assay |
In vitro cellular assays for menbutone are not commonly performed, as it is a choleretic agent. Studies may involve culturing hepatocytes and measuring bile acid production or secretion in response to the compound. Cytotoxicity may be assessed using standard viability assays.
|
| Animal Protocol |
In vivo animal studies for menbutone are conducted in animal models to assess its choleretic effects. Standard protocols involve administering the compound and measuring bile flow and composition. Its effects on digestive processes may be evaluated by measuring the activity of trypsinogen and pepsinogen. These studies confirm its efficacy as a choleretic agent.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of menbutone include a rapid onset of action, with maximum plasma levels achieved within 1 hour and lasting for roughly 10 hours. It has a molecular weight of 258.27 and a molecular formula of C₁₅H₁₄O₄. It is soluble in DMSO (>40 mg/mL). Its IUPAC name is 4-(4-methoxynaphthalen-1-yl)-4-oxobutanoic acid.
|
| Toxicity/Toxicokinetics |
Toxicological data for menbutone indicate that acute toxicity occurs at accidental high doses in rabbits, with a lethal dose of about 50. Cardiac muscle, liver and kidneys are the main target organs for menbutone toxicity. It is not recommended for use in rabbits suffering from any cardiac and hepatic disorders, especially in overdosing situations.
|
| Additional Infomation |
Menbutone is a type of butanone.
Menbutone (Genabilic acid) is an oxobutyric acid derivative that acts as a choleretic agent. It is also known as Genabilin and Naftobil. It stimulates bile secretion and has activity as trypsinogen and pepsinogen. It has been studied for its potential in treating hepatic and gastrointestinal disorders. It is not approved for human therapeutic use in many jurisdictions. |
| Molecular Formula |
C15H14O4
|
|---|---|
| Molecular Weight |
258.27
|
| Exact Mass |
258.089
|
| CAS # |
3562-99-0
|
| PubChem CID |
71818
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.249 g/cm3
|
| Boiling Point |
511.5ºC at 760 mmHg
|
| Flash Point |
196.6ºC
|
| Index of Refraction |
1.629
|
| LogP |
2.895
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
19
|
| Complexity |
339
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])[H])C1=C([H])C([H])=C(C(C([H])([H])C([H])([H])C(=O)O[H])=O)C2=C([H])C([H])=C([H])C([H])=C21
|
| InChi Key |
FHGJSJFIQNQBCK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H14O4/c1-19-14-8-6-11(13(16)7-9-15(17)18)10-4-2-3-5-12(10)14/h2-6,8H,7,9H2,1H3,(H,17,18)
|
| Chemical Name |
4-(4-methoxynaphthalen-1-yl)-4-oxobutanoic acid
|
| Synonyms |
Fel-Bis; Epanaftol; Menbutone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 40 mg/mL (~154.88 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.68 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8719 mL | 19.3596 mL | 38.7192 mL | |
| 5 mM | 0.7744 mL | 3.8719 mL | 7.7438 mL | |
| 10 mM | 0.3872 mL | 1.9360 mL | 3.8719 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
